Please login to the form below

Not currently logged in
Email:
Password:

MNK-795

This page shows the latest MNK-795 news and features for those working in and with pharma, biotech and healthcare.

Mallinckrodt offers $1.3bn for Cadence Pharma

company.". Mallinckrodt is also active in the analgesia sector and last year won priority review status from the FDA for MNK-795, a controlled-release oral formulation of oxycodone and acetaminophen

Latest news

  • FDA grants priority review to pain drug

    FDA grants priority review to pain drug. Mallinckrodt’ s MNK-795 is intended for the management of moderate to severe acute pain. ... Mallinckrodt has won priority review from the US Food and Drug Administration (FDA) for its pain drug MNK-795.

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wisepress

Wisepress is a medical bookseller promoting and selling books worldwide, both online and via the 200 European medical conferences that...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics